Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 16/20 | 1.00 |
| ▸ | EGFR | P00533 | 4/20 | 0.60 |
| ▸ | AXL | P30530 | 2/20 | 0.60 |
| ▸ | FLT4 | P35916 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 2/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.60 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.60 |
| ▸ | STK17B | O94768 | 1/20 | 0.60 |
| ▸ | STK10 | O94804 | 1/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.60 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.60 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.60 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15664191 | 0.96 | KIT (1.00) | KITEGFRAXLFLT4KDR | |
| SCHEMBL15664947 | 0.94 | KIT (1.00) | KITAXLSRC | |
| SCHEMBL15664533 | 0.93 | KIT (1.00) | KITEGFRAXL | |
| SCHEMBL15664322 | 0.90 | KIT (1.00) | KITEGFRAXLFLT4KDR | |
| SCHEMBL15663953 | 0.89 | KIT (1.00) | KITEGFRAXLFLT4KDR | |
| SCHEMBL15664568 | 0.87 | KIT (1.00) | KITEGFRAXLFLT4KDR | |
| SCHEMBL15664075 | 0.86 | KIT (1.00) | KITAXL | |
| SCHEMBL15665218 | 0.86 | KIT (1.00) | KIT | |
| SCHEMBL15664181 | 0.83 | KIT (1.00) | KIT | |
| SCHEMBL15664948 | 0.81 | KIT (1.00) | KITEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892534-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | KIT 1/4885EGFR 535/4885AXL 716/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KIT 1/4885EGFR 535/4885AXL 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.